Dimensional Fund Advisors LP increased its position in shares of Myriad Genetics Inc. (NASDAQ:MYGN) by 1.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,448,505 shares of the company’s stock after buying an additional 24,137 shares during the period. Dimensional Fund Advisors LP owned 2.06% of Myriad Genetics worth $44,324,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently made changes to their positions in MYGN. Acrospire Investment Management LLC bought a new position in shares of Myriad Genetics during the first quarter worth about $109,000. Societe Generale bought a new position in shares of Myriad Genetics during the second quarter worth about $120,000. C M Bidwell & Associates Ltd. bought a new position in shares of Myriad Genetics during the first quarter worth about $148,000. BlackRock Inc. increased its position in shares of Myriad Genetics by 123.4% in the first quarter. BlackRock Inc. now owns 4,715 shares of the company’s stock worth $176,000 after buying an additional 2,604 shares in the last quarter. Finally, Adams Diversified Equity Fund Inc. bought a new position in shares of Myriad Genetics during the second quarter worth about $187,000.
Myriad Genetics Inc. (NASDAQ:MYGN) opened at 18.62 on Friday. Myriad Genetics Inc. has a one year low of $17.66 and a one year high of $46.24. The stock has a 50 day moving average price of $20.72 and a 200 day moving average price of $29.61. The firm has a market cap of $1.29 billion, a PE ratio of 10.89 and a beta of 0.54.
Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, August 9th. The company reported $0.36 EPS for the quarter, missing the consensus estimate of $0.38 by $0.02. The business earned $186.50 million during the quarter, compared to analysts’ expectations of $187.95 million. Myriad Genetics had a net margin of 14.98% and a return on equity of 16.06%. The business’s quarterly revenue was down 1.8% compared to the same quarter last year. During the same period last year, the company earned $0.41 EPS. Equities research analysts expect that Myriad Genetics Inc. will post $1.07 EPS for the current year.
MYGN has been the topic of a number of analyst reports. Stephens set a $30.00 price target on Myriad Genetics and gave the company a “buy” rating in a report on Thursday, August 11th. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research report on Wednesday, July 27th. Barclays PLC cut Myriad Genetics from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $50.00 to $24.00 in a research report on Wednesday, August 10th. Jefferies Group lowered their price objective on Myriad Genetics from $34.00 to $20.00 and set a “hold” rating for the company in a research report on Thursday, August 11th. Finally, Gabelli cut Myriad Genetics from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $46.00 to $32.00 in a research report on Wednesday, August 10th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $31.00.
In other Myriad Genetics news, insider Mark Christopher Capone bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 19th. The shares were purchased at an average price of $21.24 per share, with a total value of $212,400.00. Following the completion of the acquisition, the insider now directly owns 146,026 shares of the company’s stock, valued at approximately $3,101,592.24. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John T. Henderson sold 30,000 shares of the stock in a transaction on Monday, September 12th. The shares were sold at an average price of $20.49, for a total value of $614,700.00. Following the completion of the transaction, the director now directly owns 49,493 shares in the company, valued at approximately $1,014,111.57. The disclosure for this sale can be found here. 5.80% of the stock is owned by corporate insiders.
About Myriad Genetics